AAC Research & Clinical Trials Awareness 3 — Questions and Answers
Question 1: Which phase of a clinical trial is the FIRST to test an experimental Alzheimer's drug in human beings?
- Phase III
- Phase II
- Phase I (Correct answer)
- Phase IV
Correct answer: Phase I
Phase I trials are the first in-human studies, focusing primarily on safety, tolerability, and dosing in a small group of participants.
Question 2: What does 'double-blind' mean in the context of an Alzheimer's clinical trial?
- Both the drug and placebo are administered intravenously
- Neither the participants nor the researchers assessing outcomes know who received the treatment or placebo (Correct answer)
- The trial is conducted at two separate research centers
- Participants are blinded to all study results until the trial ends
Correct answer: Neither the participants nor the researchers assessing outcomes know who received the treatment or placebo
In a double-blind trial, neither participants nor investigators know the treatment assignment, minimizing bias in assessment and reporting.
Question 3: The A4 Study (Anti-Amyloid Treatment in Asymptomatic Alzheimer's) targets which population?
- People with moderate-to-severe Alzheimer's disease
- Cognitively normal older adults who show amyloid buildup on PET scans (Correct answer)
- Individuals with genetic mutations guaranteeing early-onset Alzheimer's
- Patients who have already failed two standard treatments
Correct answer: Cognitively normal older adults who show amyloid buildup on PET scans
The A4 Study enrolled cognitively normal older adults with elevated amyloid to test whether removing amyloid before symptoms appear prevents decline.
Question 4: What is the role of an Institutional Review Board (IRB) in Alzheimer's research?
- To manufacture and distribute experimental drugs
- To review and approve research protocols to protect the rights and welfare of human participants (Correct answer)
- To conduct statistical analysis of trial data
- To register completed trials with the FDA
Correct answer: To review and approve research protocols to protect the rights and welfare of human participants
An IRB is an independent committee that evaluates the ethical and safety standards of research before and during a study.
Question 5: Genetic testing for the APOE ε4 allele is relevant in Alzheimer's research because it:
- Guarantees that a person will develop Alzheimer's disease
- Is the strongest known genetic risk factor for late-onset Alzheimer's and affects trial eligibility and outcomes (Correct answer)
- Is used to diagnose Alzheimer's definitively in clinical practice
- Only affects Alzheimer's risk in individuals under age 50
Correct answer: Is the strongest known genetic risk factor for late-onset Alzheimer's and affects trial eligibility and outcomes
The APOE ε4 allele is the major genetic risk factor for late-onset Alzheimer's and is often used to stratify participants in research studies.
Question 6: What is a 'run-in period' in the design of an Alzheimer's clinical trial?
- The time during which researchers are trained on trial protocols
- A pre-randomization phase used to assess adherence, washout prior medications, or establish baseline measures (Correct answer)
- The final month of a trial when data collection intensifies
- A period when participants receive double the standard dose
Correct answer: A pre-randomization phase used to assess adherence, washout prior medications, or establish baseline measures
A run-in period occurs before randomization and is used to identify adherent participants, clear previous medications, or collect stable baselines.
Question 7: Which federal website is the official registry where all U.S. clinical trials must be registered?
- NIH.gov
- FDA.gov
- ClinicalTrials.gov (Correct answer)
- CDC.gov
Correct answer: ClinicalTrials.gov
ClinicalTrials.gov is the U.S. National Library of Medicine's registry where sponsors must register clinical trials and report results.
AAC Research & Clinical Trials Awareness 3
Which phase of a clinical trial is the FIRST to test an experimental Alzheimer's drug in human beings?